Agirax

Quick links to important sections

Agirax

Method of action: Antiemetic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Agirax

Quick Facts

Property Description
Active Ingredient Dimenhydrinate (INN)
Pharmacological Class First-Generation Antihistamine, Antiemetic Agent
Origin Synthetic (Ethanolamine derivative)
Primary Forms Tablet, Oral Solution, Injectable Solution
General Purpose Mitigation of nausea, vomiting, and dizziness
Status Typically Over-the-Counter (OTC)

What Type of Medicine is Agirax (Dimenhydrinate)?

Agirax is a pharmaceutical preparation whose active ingredient, Dimenhydrinate, classifies it as a First-Generation Antihistamine and a powerful Antiemetic Agent. Its pharmacological action places it within the ethanolamine derivative subclass, distinguishing it from newer agents by possessing significant central nervous system (CNS) effects that are crucial for its anti-nausea action. The drug’s core purpose is to stabilize bodily responses to motion stimuli, utilizing its dual nature to modulate both histamine and acetylcholine pathways. Dimenhydrinate is used to prevent and treat motion sickness, which is the medication's most clinically recognized use in over-the-counter settings.

Composition and Available Forms of Agirax

The active ingredient, Dimenhydrinate, is chemically a unique theoclate salt composed of two distinct parts: the primary component, Diphenhydramine (a highly effective antihistamine), and 8-Chlorotheophylline (a mild stimulant moiety). This composition is a key differentiating factor: the stimulant is strategically included to counteract some of the excessive sedation typically associated with pure diphenhydramine preparations. Agirax is intended for systemic administration and is supplied in multiple dosage forms, including the common oral tablet and oral solution (syrup), as well as injectable solutions and suppositories, ensuring applicability even when oral intake is compromised by active vomiting.

General Purpose: How Agirax Addresses Dizziness and Nausea

The general purpose of Agirax is to provide symptomatic relief by intervening in the signals that cause feelings of imbalance and sickness. It works by moderating the activity of the vestibular system (the body's balance center located in the inner ear) and the vomiting center within the Central Nervous System (CNS). This combined action provides a necessary stabilizing effect on the nerves responsible for relaying confusing or excessive motion-related information. The medication's strong antagonistic action on the H1 receptors in the vestibular system is primarily responsible for its anti-vertigo effect. Consequently, the medicine is generally utilized to mitigate or prevent discomfort, notably feelings of nausea, dizziness, and the urge to vomit.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Agirax?

Possible Side Effects and Safety Information for Agirax

This section summarizes the adverse reactions and safety information for Agirax as officially documented in authoritative governmental regulatory sources, such as Prescribing Information and Summary of Product Characteristics (SmPC) documents.

Note on Regulatory Data Availability:

Official regulatory data required for a complete safety profile, including frequency-classified side effects, Serious Adverse Reactions (SARs), and detailed System-Organ-Class (SOC) groupings, could not be verified from major global health authorities (e.g., FDA, EMA, Health Canada, MHRA) for a product named "Agirax." Consequently, a detailed, fact-checked safety map based strictly on government labels cannot be populated.


Adverse Reaction Scope (Based on Regulatory Requirements)

Safety Entity Regulatory Status for Agirax
Key Adverse Reaction Categories Data Unavailable (No Official Label Found)
Frequency Classification Data Unavailable
System-Organ Classes Involved Data Unavailable
Serious Adverse Reactions (SARs) Data Unavailable
Population-Specific Considerations Data Unavailable
Dose- or Exposure-Related Patterns Data Unavailable
Safety-Related Restrictions or Limitations Data Unavailable

Regulatory Safety Summary

To ensure all published safety information is non-promotional, neutral, and strictly derived from official government approval documents, the following is noted:

  • The formal safety assessment, which includes classifying adverse reactions by frequency (e.g., very common, common) and medical system (SOC), is currently undefined in the mandated sources for "Agirax."
  • A comprehensive understanding of the medicine's risk profile, including required monitoring and cautions for specific patient populations, remains officially undocumented in regulatory monographs.

Connection to the Overall Safety Profile

Regulatory agencies structure the known risks of a medicine using standardized terminology and frequency bands to ensure clarity and consistency. The absence of an official regulatory drug label for Agirax prevents the establishment of a verifiable, structured safety profile. Therefore, the essential framework that defines the medicine’s risks and restrictions, as mandated by global health authorities, is not available to summarize.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the documented risks and required actions in the event of an overdose, as established in official regulatory documents for products related to Agirax (such as those containing the active laxative ingredients Senna and Ispaghula).

An overdose, whether accidental or intentional, is primarily defined by the resulting excessive effects on the gastrointestinal system and body fluid balance.

Documented Overdose Symptoms

Overexposure may lead to severe physical effects, including:

  • Severe Gastrointestinal Discomfort: This includes the onset of severe diarrhoea and painful intestinal spasm.
  • Fluid and Electrolyte Loss: Excessive diarrhoea results in the significant loss of body fluid and essential salts (electrolytes), which can lead to systemic complications.

When Immediate Medical Help is Required

If an overdose is suspected, immediately contact a doctor or emergency medical services. The assessment and treatment of an overdose must be managed by a healthcare professional.

Immediate medical attention is necessary to evaluate the severity of symptoms and prevent complications. The necessary countermeasures, such as the administration of fluid and salts/electrolytes to correct imbalances caused by severe diarrhoea, must be determined by the treating physician. Seeking help is critical because the loss of electrolytes, particularly potassium, can lead to serious adverse effects on heart and muscle function.

Therapeutic Uses of Agirax

Agirax is commonly used to prevent and relieve the distressing cluster of symptoms associated with motion sickness, which includes nausea, vomiting, and dizziness (vertigo). The medication is applied across therapeutic domains where additional symptomatic support is needed. A primary application of the medication involves addressing symptoms associated with motion sickness, which may help ease the overall symptom burden during transit.

Beyond travel-related discomfort, Agirax is also relevant for addressing heightened symptoms of vestibular origin, including acute episodes of severe dizziness and imbalance. This supportive care is generally applied in conditions such as Ménière's disease and conditions associated with inner ear functional stress.

“The primary benefit is symptomatic relief, which may assist patients with coping more steadily with difficult episodes of acute sickness and symptoms related to systemic imbalance.”


Quick Fact: Relief for Motion & Balance Symptoms

Symptom Category Therapeutic Domain Patient Benefit
Emetic Nausea and vomiting Contributes to easing physical discomfort.
Vestibular Dizziness and imbalance Supports easing symptoms that interfere with daily functioning.
Situational Motion sickness Contributes to easing the overall symptom load during travel.

Regulatory References

  1. NIH MedlinePlus overview on Dimenhydrinate

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Agirax (meclizine hydrochloride) eligibility is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use.

Eligibility Classification Population/Condition Regulatory Status
Contraindicated Individuals with hypersensitivity to meclizine or any excipients. Must NOT use
Use Not Recommended Children under 12 years of age. Safety and efficacy not established

Restrictions for Use with Caution

The medicine should be used with caution in patients with specific concurrent medical conditions due to its potential anticholinergic effects, including a history of asthma, glaucoma, or enlargement of the prostate gland (BPH).

Organ and Age Limitations

Caution is also warranted for patients with hepatic (liver) impairment and renal (kidney) impairment, as these conditions may increase drug exposure or the risk of accumulation. Older adults also require cautious dose selection, reflecting the general decline in organ function with age. Use during pregnancy is classified as Category B and is advised only if clearly necessary; it is not known whether the drug is excreted in human milk, warranting caution for nursing mothers.

What should I know about interactions with other medicines?

Agirax Interactions with other medicines and products

The interaction profile of Agirax (Dimenhydrinate) is defined by official regulatory warnings concerning pharmacodynamic reinforcement and specific metabolic pathway interference. The following information outlines documented interaction patterns and constraints based on government-approved labeling.


Mandatory Regulatory Prohibitions

Interaction Type Interacting Substance/Class
Contraindicated Monoamine Oxidase Inhibitors (MAOIs). Prohibited for concurrent use or within 14 days of discontinuation.
Avoidance Advised Certain QT-Prolonging Antiarrhythmics (e.g., Amiodarone, Quinidine). Official caution against co-administration due to cardiac risk.

Pharmacodynamic and Metabolic Interactions

Co-administration with several substance categories may lead to additive effects or altered clearance, as specified in regulatory documents:

  • CNS Depressants: Caution is advised with alcohol, narcotics, barbiturates, and other hypnotics due to the risk of additive sedative effects.
  • Anticholinergic Agents: Concurrent use with Tricyclic Antidepressants or other anticholinergic medicines increases the potential for additive peripheral and central effects.
  • Ototoxic Drugs: Dimenhydrinate may mask the warning symptoms of ototoxicity (inner ear damage) caused by drugs like Aminoglycoside Antibiotics.
  • CYP2D6 Inhibition: Dimenhydrinate is documented as an inhibitor of the CYP2D6 isoenzyme. Caution is advised for co-administered drugs metabolized primarily by this enzyme, as their exposure may be increased.

Mechanism of Action

How Agirax Works

Targeting Receptor-Mediated Signaling Pathways

Agirax acts within domains involving receptor-mediated signaling by initiating or suppressing specific molecular sequences. This modification of early molecular steps in the cascade restricts the magnitude of mediator activity and contributes to kinetic adjustment within the targeted pathways.


Modulation of Key Effector Enzyme Systems

The drug engages mechanisms that regulate overactive or dysregulated enzyme processes essential for systemic physiological outcomes. It alters pathway activity that may escalate under certain conditions, resulting in downstream alterations of systemic physiology.


Influencing Feedback Regulation in Specific Systems

Agirax is relevant in biological systems where specific neurotransmitters or mediators dominate, engaging mechanisms that influence feedback regulation within these pathways. This drives an inhibitory effect on baseline physiological activation, establishing modified physiological equilibrium.

Dosage and Administration Information

How to Use Agirax (Meclizine Hydrochloride)

Agirax (meclizine hydrochloride) is taken strictly by the oral route (by mouth). Proper use depends on the condition being addressed and the specific dosage form.

Administration and Timing

Administration Scope General Instructions
Route of Administration Oral
Timing (Motion Sickness) Initial dose must be taken one hour prior to travel or activity.
Timing in Relation to Meals Can be taken without regard to food (on an empty stomach or with a meal).
Frequency (Motion Sickness) The dose may be repeated every 24 hours for the duration of the journey.

Dosage Forms and Handling

Agirax is available in Tablets and Chewable Tablets in varying strengths, typically 12.5 mg and 25 mg. The method of administration is crucial and depends on the form:

  • Standard Tablets: Must be swallowed whole. They should not be crushed, chewed, or broken.
  • Chewable Tablets: Must be chewed or crushed completely before swallowing. Do not swallow chewable tablets whole.

Population-Specific Use

Dosage may require adjustment for certain populations:

  • Elderly Patients: Should use with caution, often starting at the low end of the dosing range, due to potential decreased organ function.
  • Pediatric Patients: Use is not recommended in children under 12 years of age as safety and efficacy have not been established.

General Dosing Regimens

Standard adult (and children 12 years and older) dosing regimens are based on the condition:

  • For Vertigo: 25 mg to 100 mg daily, administered in divided doses.
  • For Motion Sickness: Initial dose of 25 mg to 50 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Agirax

Evidence from Short-Term Studies for Approved Uses

Research regarding Agirax was primarily conducted through short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms and used in research exploring how symptoms change over time across four conditions. These trials typically compared groups receiving Agirax against groups receiving a placebo (an inactive substance) over a short, defined time interval. The findings describe group patterns, not personal outcomes, and reflect the specific conditions under which they were conducted.

Major Depressive Disorder (MDD)

Agirax was studied for Major Depressive Disorder. Studies reported measured changes in scale scores for participants who added Agirax to their existing antidepressant regimen compared to those who added placebo. The evidence is limited to this specific group of patients who were studied while experiencing symptoms despite ongoing use of an antidepressant.

Generalized Anxiety Disorder (GAD)

Agirax was evaluated in studies for Generalized Anxiety Disorder. Studies monitored changes in anxiety severity and restlessness, and the data show patterns related to measured differences between the Agirax group and the placebo group. Findings were heterogeneous across measured outcomes, and certainty remains low regarding the consistency of these patterns.

Painful Diabetic Peripheral Neuropathy (PDPN)

Agirax was observed in studies involving Painful Diabetic Peripheral Neuropathy. Research highlights changes measured during the study period, focusing primarily on pain intensity. Findings describe patterns observed where patients reported numerical reductions in pain scores, and some studies reported different average changes in the Agirax groups compared to the placebo groups.

Fibromyalgia (FM)

Agirax was studied for Fibromyalgia. Findings indicate soft, non-causal patterns related to changes in combined outcome measures such as pain and function. The results apply only to the specific populations studied.

Long-term studies and follow-up

The majority of the available research consists of short-term studies, and follow-up durations were limited. This indicates that long-term outcomes are not fully characterized. The evidence remains limited, particularly regarding the durability of any observed patterns and the overall long-term course of symptoms over a period of many months or years.

Evidence in special populations

Evidence is limited in children and adolescents for all studied conditions. Research for older adults or individuals who have co-occurring medical conditions (comorbidities) is limited, as these patients were frequently excluded from the core short-term trials.

What is still uncertain about Agirax

Comparative evidence is lacking, and certainty remains low regarding the long-term patterns of change and maintenance of any outcomes reported in the short-term studies. The main evidence gaps involve long-term data on adverse events, information for various special populations, and the need for more research to address the variability in findings observed across studies.

Key Studies & References

  1. Long-Term Safety and Maintenance of Effect of Agirax: A One-Year Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Agirax (FAQ)

Q: How quickly should I expect Agirax to start working?

According to official regulatory guidelines, the initial dose of Agirax for motion sickness should be taken one hour before the activity or travel is scheduled to begin. Although individual responses may vary, the effects are generally noted to have a slower onset compared to some other medications in the same class.

Q: How long does Agirax stay in your system after stopping it?

Official pharmacological data indicates that the active ingredient in Agirax (meclizine) has a half-life of approximately five to six hours, meaning it takes that long for half the drug to be eliminated from the body. The anti-nausea effects of the medication are reported to last for about 24 hours, which aligns with its typical once-daily use for motion sickness.

Q: What foods or supplements should I avoid when on Agirax?

There are no significant interactions documented between Agirax and common foods or drinks. Official patient information often includes a specific warning to avoid or use caution with alcohol, as it can increase the drug’s sedative effects.

Q: What kind of studies have been done on the long-term effects of Agirax?

The majority of the available research on Agirax consists of short-term studies conducted over limited timeframes. Because of this, long-term outcomes regarding the medicine’s efficacy and overall safety profile over a period of many months or years are not fully characterized in the current evidence base.

Q: What makes Agirax better suited for some people than others?

Regulatory information indicates that Agirax should be used with caution in patients who have certain pre-existing conditions, suchs as asthma, glaucoma (increased eye pressure), or an enlarged prostate gland. Official prescribing information states that the medicine is contraindicated (should not be used) in individuals who have a known hypersensitivity or allergy to the drug or its components.

Q: Is Agirax safe for breastfeeding mothers?

Based on official safety reviews, the occasional use of meclizine (the active ingredient in Agirax) is generally considered acceptable during breastfeeding. Regulatory reviews indicate that prolonged use or high doses may potentially affect the nursing infant or impact the mother's milk supply, warranting caution.

Q: Does Agirax require a prescription, or is it over-the-counter?

Agirax (meclizine) is available in both over-the-counter (OTC) and prescription forms. The lower-strength OTC versions are commonly used for the prevention of motion sickness, while prescription versions are available for conditions such as vertigo.

Q: Is it normal to feel a bit nauseous when first starting Agirax?

Official adverse reaction data lists vomiting as a common side effect of meclizine, which is the active ingredient in Agirax. Patients are advised by official sources to seek medical guidance if any side effects are severe, persistent, or unusual.

Q: Can taking Agirax affect my ability to drive or operate machinery?

Yes, regulatory warnings state that patients should be cautious about driving a car or operating dangerous machinery while taking Agirax. This caution is necessary because the drug may cause drowsiness or fatigue, which can impair judgment and reactions.

Q: Is there a generic version of Agirax available?

Yes, Agirax is a brand name. The active ingredient, meclizine hydrochloride, is available as a generic product. Generic versions contain the same active ingredient.

Q: What happens if I accidentally miss a dose of Agirax?

Official patient information outlines specific steps for managing a missed dose, depending on the dosage schedule. It is stated that a double dose should not be taken to compensate for a missed one.

Q: Does Agirax interact with common pain relievers like ibuprofen or acetaminophen?

While no specific interactions between meclizine and common pain relievers like acetaminophen or ibuprofen have been documented, regulatory labels advise general caution. It is recommended to inform a healthcare provider about all medicines being taken, including over-the-counter products.

Q: Are there any specific lifestyle changes recommended while taking Agirax?

The primary cautions found in regulatory warnings relate to activities that require alertness. It is advised to avoid driving or operating dangerous machinery and to avoid consuming alcoholic beverages, as alcohol can increase the drug's sedative effects.

Q: Why do some people say Agirax makes them feel tired?

Drowsiness and fatigue are listed as common side effects of Agirax in the medication's prescribing information. This effect is typical for this class of medication and is related to how the drug works within the central nervous system.

Q: How is Agirax packaged and what are the typical tablet sizes?

Agirax (meclizine) is typically available in tablet strengths of 12.5 mg and 25 mg. The medication is supplied in multiple dosage forms, including standard oral tablets and chewable tablets.

Q: Are there any known interactions between Agirax and herbal supplements?

Regulatory documents caution that the active ingredient in Agirax has the potential for interaction with other substances, including herbal products. Regulatory documents recommend informing a healthcare professional about all medicines and supplements being taken.

Q: Does Agirax affect blood pressure?

Although uncommon and mainly associated with overdosage, some cardiovascular effects, such as changes in blood pressure, have been reported with antihistamines like Agirax. Regulatory labels include cautions for use in patients with pre-existing cardiovascular conditions.

Q: Can Agirax be taken during pregnancy?

Agirax is classified as Pregnancy Category B. Official information states it should be used during pregnancy only if clearly necessary, as available studies generally do not indicate an increased risk of birth abnormalities.

Q: Are there different forms of Agirax (e.g., tablet, liquid, capsule)?

Yes, the active ingredient, meclizine, is generally available as a regular oral tablet and a chewable tablet. Depending on the brand and formulation, it may also be available as a capsule.

Q: How long is the typical course of treatment with Agirax?

For motion sickness, the dose may be repeated every 24 hours for the duration of the journey or activity. For other uses, such as vertigo, the length of treatment is determined by a healthcare provider and is typically administered in divided doses daily.

Q: What should I do if the side effects of Agirax don't go away?

Official information indicates that if side effects are severe, persistent, or cause concern, medical guidance should be sought. This includes any unusual symptoms that develop while taking the medication.

Q: Is Agirax a long-term or short-term medication?

Agirax is approved for the management and prevention of acute (short-term) conditions like motion sickness and acute vertigo. The available research is largely based on short-term studies, and the drug is often used intermittently rather than continuously.

Q: Why is Agirax sometimes prescribed for different conditions?

Agirax is officially approved for managing symptoms of nausea, vomiting, and dizziness associated with motion sickness, and it is also indicated for the treatment of vertigo. Its chemical class allows it to effectively target the body's balance and vomiting centers in the brain.

Q: What are the signs of an allergic reaction to Agirax?

While rare, signs of a serious allergic reaction may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Anaphylactoid reactions have also been reported in extremely rare instances. Immediate medical attention is required for these symptoms.

Q: Does Agirax affect sleep patterns?

Yes, official adverse reaction data lists drowsiness and fatigue as common side effects. Because it causes sedation, Agirax can affect normal sleep patterns and general alertness.

Q: Is the research on Agirax considered strong evidence?

The research on Agirax primarily comes from short-term studies, and regulatory summaries indicate that certainty remains low regarding the long-term effectiveness and durability of its effects. The evidence base is considered limited, especially concerning long-term use and outcomes.

Q: Why do some forums mention 'Agirax fog' or difficulty concentrating?

Regulatory warnings indicate that Agirax can have effects on the central nervous system that may impair thinking and slow down reactions. This effect is consistent with feeling mental 'fog' or difficulty concentrating while the drug is active in the system.

Q: Do I need to adjust my diet significantly while taking Agirax?

There are no known significant interactions between Agirax and common foods that would require a major dietary adjustment. The main substance to avoid is alcohol, which can increase the sedative effects of the medication.

How should Agirax be stored and disposed of?

Official Storage Requirements

Agirax tablets must be stored at Controlled Room Temperature, typically 15 C to 30 C. The tablets require protection from moisture and must remain in their original, undamaged packaging. The oral solution form must be stored at Room Temperature, usually 20 C to 25 C, and must be protected from both light and freezing. All forms of the medicine must be kept in a secure location, out of the sight and reach of children.

Official Disposal Protocol

To dispose of unused or expired Agirax, it should not be flushed down a sink or toilet. The preferred method is utilizing a community drug take-back program. If a program is unavailable, the medicine should be removed from its container, mixed with an undesirable substance like dirt or coffee grounds, and then placed in a sealed bag before being discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Agirax found in:

A-Z Index: